Related Experiment Video
Updated: Aug 1, 2026
07:00
Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
Specification of limits for particulate contamination in pharmaceutical dosage forms
The Journal of Pharmacy and Pharmacology
|October 1, 1982
Summary
This study proposes using both mean and standard deviation for particulate contamination limits in parenteral solutions and aerosols. The ST statistic is recommended for measuring container-to-container variation effectively.
Area of Science:
- Pharmaceutical Science
- Quality Control
- Analytical Chemistry
Background:
- Particulate contamination is a critical quality attribute for parenteral solutions and metered-dose aerosols.
- Current control limits may not adequately address variability in particle counts.
- Ensuring product safety and efficacy necessitates robust methods for assessing particulate contamination.
Purpose of the Study:
- To discuss and propose improved methods for setting limits on particulate contamination.
- To evaluate statistical approaches for controlling particle counts in pharmaceutical products.
- To address container-to-container variation in particulate contamination measurements.
Main Methods:
- Review of existing methods for particulate contamination control.
- Statistical analysis of particle count data from multiple containers.
- Application of the ST statistic for assessing variability.
Main Results:
- The study suggests that limits should incorporate both the mean and standard deviation of particle counts.
- The ST statistic is identified as a suitable metric for evaluating container-to-container variation.
- This approach aims for a target value of zero contamination.
Conclusions:
- Implementing limits based on mean and standard deviation enhances control over particulate contamination.
- The ST statistic provides a robust measure for container-to-container variability in pharmaceutical manufacturing.
- These methods contribute to improved quality and safety of parenteral solutions and aerosols.
Related Concept Videos
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...